 -XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardshipDUBLIN, July 28, 2020 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV announced today that the European Commission EC has issued a legally binding decision for approval of the marketing authorization application for XENLETATM lefamulin for the treatment of community-acquired pneumonia CAP in adults following a review by the European Medicines Agency EMA. The EMA approval of XENLETA in CAP patients when it is considered inappropriate to use antibacterial agents that are commonly recommended for initial treatment or when these agents have failed paves the way for the launch of XENLETA across Europe. The U.S. Food and Drug Administration FDA approved XENLETA for the treatment of adult patients with community-acquired bacterial pneumonia CABP in August 2019.The marketing authorization of XENLETA provides an important step forward for patients with CAP, offering the first new antibiotic class approved by the EMA in nearly two decades, said Ted Schroeder, chief executive officer of Nabriva Therapeutics. XENLETA has a novel mechanism of action, with targeted in vitro activity against the most common pathogens associated with CAP, and a low propensity for the development of resistance. Along with its short course, monotherapy regimen, and availability of both intravenous IV and oral formulations, XENLETA offers an important empiric treatment option for adult patients with CAP aligned with the core principles of antimicrobial stewardship. We believe the approval of XENLETA is a significant advancement in the fight against antimicrobial resistance and we are excited to bring this critically needed medicine to patients throughout Europe.The EMA approval is based on efficacy data from the Lefamulin Evaluation Against Pneumonia LEAP 1 and LEAP 2 studies and a safety database of 1,242 study participants. In the two Phase 3 clinical trials, the European Medicines Agencys co-primary endpoint was the Investigator Assessment of Clinical Response IACR at Test of Cure TOC in both the clinically evaluable CE and modified intent-to-treat mITT populations. Both studies established XENLETA to be non-inferior to the standard-of-care moxifloxacin in the treatment of adults with CAP independently and when the pooled data were analyzed across PORT scores of II-V. In the pooled analysis, the IACR success rate at TOC in the modified Intent-to-Treat mITT population was 85 percent in the XENLETA group and 87.1 percent in the moxifloxacin group treatment difference 2.2 percent; 95 percent confidence interval CI: 5.9, 1.6, and 88.5 percent in the lefamulin group and 91.8 percent in the moxifloxacin group treatment difference 3.3 percent; 95 percent CI: 6.8, 0.1 in the clinically evaluable population. In these trials, lefamulin was generally well-tolerated. The most frequently reported adverse reactions were administration site reactions, diarrhea, nausea, vomiting, hepatic enzyme elevation, headache, hypokalemia and insomnia.About CAPApproximately three to four million cases of pneumonia occur annually in the EU Gibson et al, 2013. Data from the Global Burden of Disease 2015 Study reported that lower respiratory tract infections, including pneumonia, were the third most common cause of death worldwide and the most common cause of infectious death globally, claiming three million lives annually GBD, 2016; WHO, 2018. The impact on morbidity and mortality associated with community-acquired pneumonia is magnified in older patients, where data have shown that mortality is associated with advancing age Welte et al, 2012; Cillóniz et al, 2013; Ochoa-Gondar et al, 2008. Approximately 90 percent of deaths due to pneumonia occur in people over 65 years old EC, 2009a.About Nabriva TherapeuticsNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA lefamulin injection, lefamulin tablets, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia CABP. Nabriva Therapeutics is also developing CONTEPOTM fosfomycin for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections cUTI, including acute pyelonephritis.About XENLETAXENLETA lefamulin is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team. It is designed to inhibit the synthesis of bacterial protein, which is required for bacteria to grow. XENLETAs binding occurs with high affinity, high specificity and at molecular sites that are different than other antibiotic classes. Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP. In these trials, XENLETA was compared with moxifloxacin and in one trial, moxifloxacin with and without linezolid. Patients who received XENLETA had similar rates of efficacy as those taking moxifloxacin alone or moxifloxacin plus linezolid. The most frequently reported adverse reactions were administration site reactions 7, diarrhea 7, nausea 4, vomiting 2, hepatic enzyme elevation 2, headache 1, hypokalaemia 1 and insomnia 1. Administration site reactions led to discontinuation in 1 of patients; gastrointestinal disorders were predominantly associated with the oral formulation and led to treatment discontinuation in 1 of patients.For more information about Xenleta please refer to the Summary of Product Characteristics SmPc at: StatementsAny statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about Nabriva Therapeutics ability to successfully launch and commercialize XENLETA for the treatment of CABP or CAP, including the availability of and ease of access to XENLETA in Europe and through major U.S. specialty distributors, marketing exclusivity and patent protection for XENLETA, the development of CONTEPO for cUTI, the clinical utility of XENLETA for CABP and of CONTEPO for cUTI, plans for and timing of the review of regulatory filings for CONTEPO, efforts to bring CONTEPO to market, the market opportunity for and the potential market acceptance of XENLETA for CABP or CAP and CONTEPO for cUTI, the development of XENLETA and CONTEPO for additional indications, the development of additional formulations of XENLETA and CONTEPO, plans to pursue research and development of other product candidates, the sufficiency of Nabriva Therapeutics existing cash resources and its expectations regarding anticipated revenues from product sales and how far into the future its existing cash resources will fund its ongoing operations and other statements containing the words anticipate, believe, estimate, expect, intend, may, plan, predict, project, target, potential, likely, will, would, could, should, continue, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics ability to successfully implement its commercialization plans for XENLETA and whether market demand for XENLETA is consistent with its expectations, Nabriva Therapeutics ability to build and maintain a sales force for XENLETA, the content and timing of decisions made by the European Commission, the U.S. Food and Drug Administration and other regulatory authorities, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of CONTEPO for the treatment of cUTI, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics annual and quarterly reports and other filings on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments will cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics views as of any date subsequent to the date of this press release.CONTACTS:For InvestorsGary SenderNabriva Therapeutics MediaMike BeyerSam Brown 